Close Menu

BARCELONA – Two new breast cancer studies presented at the annual meeting of the European Society for Medical Oncology in Barcelona on Sunday showed that the addition of CDK4/6 inhibitors to fulvestrant therapy led to higher overall survival in HR-positive, HER2-negative breast cancer patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.